Ipamorelin (IPA) is a highly selective, third-generation growth hormone secretagogue (GHS) and ghrelin receptor agonist. Originally developed for its high binding affinity to the ghrelin receptor, this pentapeptide is distinguished in clinical research by its ability to stimulate a significant release of endogenous growth hormone (GH) without the associated spikes in cortisol, prolactin, or acetylcholine typically seen with older generation secretagogues.

Because it mimics the natural pulsatile release of GH, Ipamorelin is an ideal candidate for long-term cellular research, studies on bone density retention, and muscle tissue recovery protocols. It is highly stable and frequently utilized in comparative studies alongside other GHRH analogues.

Key Features & Research Benefits

• High Selectivity: Specifically targets the ghrelin receptor to stimulate GH release without triggering unwanted adrenocorticotropic hormone (ACTH) pathways.
• Favorable Safety Profile: Does not significantly elevate cortisol or prolactin levels, making it ideal for studies requiring strict control over secondary hormonal fluctuations.
• Synergistic Potential: Frequently researched in combination with GHRH analogues (such as CJC-1295) to observe amplified, sustained growth hormone secretion.
• High Purity Synthesis: Manufactured under strict laboratory conditions to ensure >99% purity for reliable and reproducible assay results.

Technical Specifications